[The Efficacy of Fesoterodine Switched from Solifenacin for Overactive Bladder Patients]

We investigated the efficacy of Fesoterodine, in 51 patients who did not respond to treatment with Solifenacin from January 2017 to December 2018. We assessed the overactive bladder symptom score (OABSS), thirst, constipation, and residual urine at baseline, as well as at 3 and 6 months from the start of drug administration. The mean age of the patients was 83. 0±6. 55 years. The OABSS indicated significant improvement in urge urinary incontinence and residual urine at 6 months, and significant aggravation in urgency at 3 months. Thus, Fesoterodine is considered useful for patients who did not respond to treatment with Solifenacin.